Flputnam Investment Management Co. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Flputnam Investment Management Co. acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,761 shares of the biopharmaceutical company’s stock, valued at approximately $831,000.

Other hedge funds also recently bought and sold shares of the company. Global Retirement Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $570,000. SCS Capital Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $34,784,000. Bank of New York Mellon Corp acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $148,128,000. Focus Partners Advisor Solutions LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $341,000. Finally, S&CO Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $2,227,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $224.60 on Tuesday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The stock’s 50 day moving average is $271.51 and its two-hundred day moving average is $300.10. The company has a market capitalization of $30.05 billion, a PE ratio of 41.75 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.51) earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays lowered their target price on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Chardan Capital reissued a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. HC Wainwright lowered their price target on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Oppenheimer dropped their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.